Summit Biolabs Passes Significant Milestones
Dear Investors & Friends of Summit Biolabs:
We are pleased to announce that Summit Biolabs achieved two significant
milestones last week. First, we surpassed a significant benchmark by processing
more than 250,000 tests year-to-date for COVID-19 in our CLIA laboratory in
Aurora, Colorado. These tests were performed using our own commercial
laboratory-developed, direct-to-PCR tests for COVID-19, SwabFAST™ and
SalivaFAST™. Second, we demonstrated proof of concept for the first direct-to-PCR
multiplex test for influenza A/B and COVID-19 performed on swab samples in our
laboratory. Validation studies are ongoing.
Bob Blomquist, Chief Executive Officer of Summit Biolabs commented, “We are
proud of our scientists for their biotechnology achievements that improve public
health. And we applaud the diligent and hardworking laboratory technicians who
work tirelessly to perform accurate and timely tests on such a high volume of
samples. It has been a challenging and rewarding year coming alongside public
health and healthcare providers to help combat the COVID-19 pandemic in
Further, Mr. Blomquist stated, “we are excited to be the first to show that a
combination direct to PCR test for Flu and COVID is possible.” As we are
experiencing significant growth in sample volume, the State of Colorado
Department of Public Health and Environment is forecasting a continued increase
during the upcoming months. We anticipate significant demand for our direct to
PCR Flu-COVID test this winter.
About Summit Biolabs
Summit Biolabs is a commercial-stage molecular diagnostics company harnessing
the power of liquid-biopsy to rapidly detect diseases like COVID-19, Influenza
A/B, bacterial infections, and sexually transmitted diseases.
Summit Biolabs was spun out of the University of Colorado Anschutz Medical
Campus. The company leveraged its competencies in viral detection in saliva and
direct to PCR platform technology to help combat the pandemic. Summit
developed and deployed two highly accurate, rapid, and high-throughput PCR
tests for COVID-19 diagnosis. These commercial laboratory-developed tests
eliminate the time and cost of nucleic acid extraction, while significantly
improving the turn-around-time for results.
Summit Biolabs has ongoing test development projects capitalizing on their direct
to PCR platform technology for other indications. The company’s high-complexity,
molecular diagnostics CLIA laboratory is located at Bioscience 3 on the Fitzsimons
Innovation Campus in Aurora, Colorado.